Agenus Stock Forecast, Price & News

Agenus (NASDAQ:AGEN) Frequently Asked Questions

Is Agenus a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Agenus in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Agenus stock.
View analyst ratings for Agenus or view top-rated stocks.

How has Agenus' stock been impacted by Coronavirus?

Agenus' stock was trading at $2.72 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, AGEN stock has increased by 4.4% and is now trading at $2.84.
View which stocks have been most impacted by COVID-19.

Are investors shorting Agenus?

Agenus saw a increase in short interest in the month of December. As of December 31st, there was short interest totaling 24,620,000 shares, an increase of 31.9% from the December 15th total of 18,670,000 shares. Based on an average daily trading volume, of 4,360,000 shares, the days-to-cover ratio is presently 5.6 days.
View Agenus' Short Interest.

When is Agenus' next earnings date?

Agenus is scheduled to release its next quarterly earnings announcement on Monday, March 21st 2022.
View our earnings forecast for Agenus.

How were Agenus' earnings last quarter?

Agenus Inc. (NASDAQ:AGEN) posted its earnings results on Tuesday, November, 9th. The biotechnology company reported $0.69 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.46 by $0.23. The biotechnology company earned $252.95 million during the quarter, compared to analyst estimates of $183.11 million. During the same quarter in the prior year, the business posted ($0.28) EPS.
View Agenus' earnings history.

What price target have analysts set for AGEN?

2 equities research analysts have issued 1-year price targets for Agenus' stock. Their forecasts range from $11.00 to $12.00. On average, they expect Agenus' stock price to reach $11.50 in the next twelve months. This suggests a possible upside of 304.9% from the stock's current price.
View analysts' price targets for Agenus or view top-rated stocks among Wall Street analysts.

Who are Agenus' key executives?

Agenus' management team includes the following people:

• Garo H. Armen, Chairman & Chief Executive Officer (LinkedIn Profile)
• Christine M. Klaskin, Chief Financial & Accounting Officer, VP-Finance (LinkedIn Profile)
• Marc van Dijk, Chief Technology Officer
• Steven O’Day, Chief Medical Officer
• Donald Vidic, Vice President & Head-Commercial

What is Garo H. Armen's approval rating as Agenus' CEO?

2 employees have rated Agenus CEO Garo H. Armen on Glassdoor.com. Garo H. Armen has an approval rating of 56% among Agenus' employees. This puts Garo H. Armen in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Agenus' key competitors?

Some companies that are related to Agenus include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Repligen (RGEN), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Novavax (NVAX) and Arena Pharmaceuticals (ARNA).
View all of AGEN's competitors.

What other stocks do shareholders of Agenus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Agenus investors own include (ROSG) (ROSG), Exelixis (EXEL), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), OPKO Health (OPK), Inovio Pharmaceuticals (INO), ADMA Biologics (ADMA), Gilead Sciences (GILD), Matinas BioPharma (MTNB) and RedHill Biopharma (RDHL).

What is Agenus' stock symbol?

Agenus trades on the NASDAQ under the ticker symbol "AGEN."

Who are Agenus' major shareholders?

Agenus' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Diversified Trust Co (0.02%) and Cutler Group LP (0.00%). Company insiders that own Agenus stock include Agenus Inc, Christine M Klaskin, Corp Incyte, Garo H Armen and Steven J O'day.
View institutional ownership trends for Agenus.

Which institutional investors are selling Agenus stock?

AGEN stock was sold by a variety of institutional investors in the last quarter, including Cutler Group LP. Company insiders that have sold Agenus company stock in the last year include Christine M Klaskin, Garo H Armen, and Steven J O'day.
View insider buying and selling activity for Agenus or view top insider-selling stocks.

Which institutional investors are buying Agenus stock?

AGEN stock was purchased by a variety of institutional investors in the last quarter, including Diversified Trust Co.
View insider buying and selling activity for Agenus or or view top insider-buying stocks.

How do I buy shares of Agenus?

Shares of AGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Agenus' stock price today?

One share of AGEN stock can currently be purchased for approximately $2.84.

How much money does Agenus make?

Agenus has a market capitalization of $729.40 million and generates $88.17 million in revenue each year. The biotechnology company earns $-180.91 million in net income (profit) each year or ($0.12) on an earnings per share basis.

How many employees does Agenus have?

Agenus employs 359 workers across the globe.

What is Agenus' official website?

The official website for Agenus is agenusbio.com.

Where are Agenus' headquarters?

Agenus is headquartered at 3 FORBES ROAD, LEXINGTON MA, 02421.

How can I contact Agenus?

Agenus' mailing address is 3 FORBES ROAD, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at (781) 674-4400, via email at [email protected], or via fax at 781-674-4200.